Source link : https://www.newshealth.biz/health-news/durvalumab-is-not-superior-to-cetuximab-in-head-neck-cancer/
TOPLINE: Compared with cetuximab with concurrent radiotherapy, adjuvant durvalumab alongside radiotherapy did not enhance outcomes in patients with head and neck squamous cell carcinoma (HNSCC) who are ineligible for cisplatin. METHODOLOGY: Although cisplatin with concurrent radiotherapy is the standard treatment for advanced HNSCC, cisplatin is contraindicated in many patients. Optimal management of patients considered unfit […]
Author : News Health
Publish date : 2024-12-31 13:17:43
Copyright for syndicated content belongs to the linked Source.